12 results match your criteria: "Christine Kühne-Center for Allergy Research and Education (Davos)[Affiliation]"
Acute generalized exanthematous pustulosis: European expert consensus for diagnosis and management.
J Eur Acad Dermatol Venereol
November 2024
ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN Skin), Paris, France.
Article Synopsis
- Acute generalized exanthematous pustulosis (AGEP) is a rare, typically drug-induced rash that presents as pustules and lacks solid evidence for effective treatment with corticosteroids, yet they are commonly prescribed.
- The ToxiTEN group, comprising European dermatologists and allergologists, created recommendations for diagnosing and managing AGEP based on their expertise and literature review.
- These expert guidelines outline necessary healthcare professionals, diagnostic processes, management strategies, and follow-up care, emphasizing the importance of a collaborative approach to treatment.
Article Synopsis
- * In Europe, several new systemic therapies for AD have been approved, including biologics like dupilumab, tralokinumab, and lebrikizumab, as well as oral JAK inhibitors like baricitinib, upadacitinib, and abrocitinib.
- * The update includes insights on the long-term safety and efficacy of these treatments, newly issued guidelines for patients at risk, and a look at emerging therapies currently being tested in Phase III trials.
Development of a clinical algorithm to predict phenotypic switches between atopic dermatitis and psoriasis (the "Flip-Flop" phenomenon).
Allergy
January 2024
Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.
Article Synopsis
- Atopic dermatitis (AD) and psoriasis vulgaris (PV) are two distinct skin conditions that can sometimes lead to a "Flip-Flop" phenomenon, where patients switch from one disease to the other during treatment.
- Researchers created and validated a diagnostic algorithm in a study of 300 patients to identify these Flip-Flop cases, enhancing it further with machine learning technology.
- The algorithm showed high accuracy (89.7%) and specific sensitivities for identifying Flip-Flop patients, marking it as the first validated tool for this purpose.
Evidence for a restoration of TLR2 response in epidermal dendritic cells in atopic dermatitis by topical anti-inflammatory therapy.
Allergy
January 2024
Department of Dermatology and Allergy, and Christine Kühne Center for Allergy Research and Education Davos (CK-CARE), University Hospital Bonn, Bonn, Germany.
Founder Variants in KRT5 and POGLUT1 Are Implicated in Dowling-Degos Disease.
J Invest Dermatol
January 2024
Institute of Human Genetics, University of Bonn, Medical Faculty & University Hospital Bonn, Bonn, Germany. Electronic address:
Treatment of chronic nodular prurigo with intravenous naloxone during pregnancy.
J Eur Acad Dermatol Venereol
July 2023
Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.
IL-13, periostin and dipeptidyl-peptidase-4 reveal endotype-phenotype associations in atopic dermatitis.
Allergy
January 2023
Department of Dermatology and Allergy, University Hospital Bonn, Venusberg-Campus 1, Bonn, Germany.
Background: The heterogeneous (endo)phenotypes of atopic dermatitis (AD) require precision medicine. Currently, systemic therapy is recommended to patients with an Eczema Area and Severity Index (EASI)≥16. Previous studies have demonstrated an improved treatment response to the anti-interleukin (IL)-13 antibody tralokinumab in AD subgroups with elevated levels of the IL-13-related biomarkers dipeptidyl-peptidase (DPP)-4 and periostin.
View Article and Find Full Text PDFFrom Skin Barrier Dysfunction to Systemic Impact of Atopic Dermatitis: Implications for a Precision Approach in Dermocosmetics and Medicine.
J Pers Med
May 2022
La Roche-Posay International, 92300 Levallois-Perret, France.
Atopic dermatitis (AD) affects up to 20% of children and is considered the starting point of the atopic march with the development of food allergy, asthma, and allergic rhinitis. The heterogeneous phenotype reflects distinct and/or overlapping pathogenetic mechanisms with varying degrees of epidermal barrier disruption, activation of different T cell subsets and dysbiosis of the skin microbiome. Here, we review current evidence suggesting a systemic impact of the cutaneous inflammation in AD together with a higher risk of asthma and other comorbidities, especially in severe and persistent AD.
View Article and Find Full Text PDFMachine Learning-Based Deep Phenotyping of Atopic Dermatitis: Severity-Associated Factors in Adolescent and Adult Patients.
JAMA Dermatol
December 2021
Allergy Unit, Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland.
Article Synopsis
- Atopic dermatitis (AD) is a common and complex skin condition that varies greatly among patients, highlighting the need for personalized medical approaches.
- Researchers conducted a study on 367 patients to explore factors linked to the severity of AD, using specific measurements and machine learning techniques.
- Findings revealed that certain characteristics, like atopic stigmata and high levels of immunoglobulin E, increased the likelihood of severe AD, while being female or in specific age groups reduced that risk.
Measuring Atopic Dermatitis Disease Severity: The Potential for Electronic Tools to Benefit Clinical Care.
J Allergy Clin Immunol Pract
April 2021
Innovaderm Research, Montréal, QC, Canada; Division of Dermatology, Department of Medicine, McGill University, Montréal, QC, Canada; The Research Institute of the McGill University Health Center, Montréal, QC, Canada. Electronic address:
Severity of atopic dermatitis (AD) correlates with impact on health-related quality of life (HRQoL), work productivity, and burden on health systems. Tools to measure severity inform regulatory approval, drug access, and value- or measurement-based care. A core set of instruments for measuring AD has been established.
View Article and Find Full Text PDFJAK1/2 inhibition impairs the development and function of inflammatory dendritic epidermal cells in atopic dermatitis.
J Allergy Clin Immunol
June 2021
Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany; Christine Kühne-Center for Allergy Research and Education Davos, Davos, Switzerland.
Background: Janus kinase (JAK) inhibitors are a new class of therapeutic compounds for dermatological diseases. In atopic dermatitis (AD), data of clinical phase III trials show rapid improvement of pruritus and significant reduction of inflammation within the first weeks with a favorable safety profile. However, their mode of action in AD is not fully understood.
View Article and Find Full Text PDF